Well to follow "Punter" Ponting's phraseology "Epichem is out/gone" and will not be recorded as a tick on managements' CVs.
Not sure what will keep them all occupied now Epichem is gone, perhaps closely monitoring PAA's consultants activities and trial status so no more unnecessary surprises.
Management's performance smacks of a deliberate effort to stretch out the trialling process pre-commerciality until or no sooner than patent expiry in 2024, yet they constantly confirm patent expiry plays no part in the decision making/timelines. MND to me, although a godsend, just provided a golden opportunity to utilize up more time with FightMND funding and allow the other planned trials to be put on the back-burner or continued at a snails pace (canines).
Hey but I am confident of success for MPL as the science will ensure that and hopefully the patients in immediate need feel the benefit sooner rather than later
PAA Price at posting:
8.0¢ Sentiment: Buy Disclosure: Held
(20min delay)